| | Survival | p-value |
|---|
| | at 12 months (%) | at 24 months (%) | univariate Analysis | multivariate Analysis |
|---|
| Age |
| ≤ 65 years | 56 | 19 | | |
| > 65 years | 80 | 27 | 0.676 | |
| Gender |
| Female | 80 | 20 | | |
| Male | 65 | 23 | 0.629 | |
| Karnofsky performance status |
| > 80% | 75 | 30 | | |
| ≤ 80% | 55 | 10 | 0.041 | 0.077 |
| UICC stage |
| III | 64 | 21 | | |
| IV | 100 | 33 | 0.537 | |
| T category |
| 1–2 | 67 | 0 | | |
| 3–4 | 68 | 28 | 0.395 | |
| N category |
| 0–1 | 33 | 0 | | |
| 2–3 | 71 | 25 | 0.299 | |
| Histology |
| Squamous cell carcinoma | 69 | 25 | | |
| Non- Squamous cell carcinoma | 67 | 20 | 0.935 | |
| Tobacco consumption (PY) |
| 0 | 75 | 25 | | |
| 20–40 | 50 | 12,50 | | |
| > 40 | 73 | 27 | 0.758 | |
| Grading |
| Moderately differentiated | 50 | 50 | | |
| Poorly differentiated | 67 | 19 | | |
| anaplastic | 100 | 50 | 0.758 | |
| PD-L1 expression |
| 0% | 86 | 29 | | |
| ≥ 1% | 50 | 19 | 0.048 | 0.648 |
| CD8+ TILs density |
| ≤ 40% | 70 | 40 | | |
| > 40% | 61 | 17 | 0.055 | |
| TIME type |
| I | 100 | 60 | | |
| II | 50 | 20 | | |
| III | 71 | 14 | | |
| IV | 40 | 20 | 0.05 | 0.048 |
